NEW YORK (GenomeWeb News) – Intrexon announced after the close of the market on Tuesday the closing of its initial public offering raising $184 million in gross proceeds.

The Germantown, Md.-based synthetic biology firm said it sold about 11.5 million shares of its common stock at $16 per share. About 10 million shares were sold as part of the initial offering, and another 1.5 million shares were sold to the underwriters of the offering as part of their overallotment option.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.